Chronic Kidney Disease Is More Common in the Cancer Population
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Modifiable risk factors accounted for only a fraction of the difference in stone rates between the sexes, according to investigators.
The prevalence of CKD-related sarcopenia may be higher than ageing-related sarcopenia.
The proportion of patients with lupus nephritis achieving renal response with belimumab increased during a 6-month extension study.
In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.
Male sex is independently associated with a nearly 2-fold increased risk for in-hospital death, among patients with CKD.
In a community-based dialysis program, nearly 10% of patients successfully converted from 3 to 2 hemodialysis sessions per week.